Publications
89
Citations
463
Est. group size
~11
Recurring co-author estimate
Active years
12
Publishing since 2015
This record is associated with early-phase clinical trials in oncology, including studies of new drug compounds for cancers such as glioblastoma and Epstein-Barr virus-positive nasopharyngeal cancer, alongside pharmacokinetic and pharmacodynamic analyses. The broader publication list also spans unrelated topics such as medical education, aging policy, veterinary vaccination, and materials chemistry, suggesting the name may be linked to multiple distinct research efforts or contributions rather than a single focused research program.
Publication output was low and sporadic from 2017 to 2020, then increased notably from 2021 onward, peaking sharply in 2024 before slightly declining in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies
Clinical Cancer Research · 2025
- Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Clinical Cancer Research · 2025
- Data from First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies
2025
- Supplementary Data 1 from First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies
2025
- Supplement Figure 1 from First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies
2025
- Supplement Figure 2 from First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies
2025
- Data from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
2025
- Supplementary Figure 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
2025
- Supplementary Table 1 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
2025
- Supplementary Table 2 from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
2025
- Strategies to Bridge the Gap between Generation Z Students and Professors in Medical Universities
Journal of Guilan University of Medical Sciences · 2025
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial
Nature Cancer · 2024
- High-performance photocatalytic degradation and antifungal activity of chromium-doped nickel oxide nanoparticles
Analytical Sciences · 2024
- Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients
Biomedicines · 2024
- Moral Disengagement: When New Unethical Behaviors Become Justifiable
Iranian Journal of Medical Ethics and History of Medicine · 2024
- Pharmaceutics×3
- Journal of Pharmacology and Experimental Therapeutics×3
- Clinical Cancer Research×2
- Molecules×2
- Cancer Research Communications×2
- Josie A. Silvaroli
Medicine · The Ohio State University
- Mahesh R. Nepal
Medicine · The Ohio State University
- Anika T. Chowdhury
Medicine · The Ohio State University
- Navjotsingh Pabla
Medicine · The Ohio State University
- Kevin M. Huang
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile